NCT02134314View on ClinicalTrials.gov

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 13, 2017

Study Completion Date

March 13, 2017

Conditions
End Stage Renal DiseaseKidney FailureDelayed Graft FunctionIschemic Reperfusion Injury
Interventions
DRUG

C1 Esterase Inhibitor

C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses

DRUG

Placebo

Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

Cedars-Sinai Medical Center

OTHER

NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI | Biotech Hunter | Biotech Hunter